Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
0.0741
+0.0053 (7.70%)
Jun 12, 2025, 4:00 PM - Market closed
Onconetix Revenue
In the year 2024, Onconetix had annual revenue of $2.52M with 4,217.31% growth. Onconetix had revenue of $711.98K in the quarter ending December 31, 2024, with 1,117.78% growth.
Revenue (ttm)
$2.52M
Revenue Growth
+4,217.31%
P/S Ratio
0.00
Revenue / Employee
$385,063
Employees
5
Market Cap
3.29M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ONCO News
- 1 day ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
- 21 days ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
- 21 days ago - Onco-Innovations Uplists to Cboe Canada - Business Wire
- 2 months ago - Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewsWire
- 3 months ago - Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress - GlobeNewsWire
- 6 months ago - Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing - GlobeNewsWire
- 8 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire
- 9 months ago - Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewsWire